{"id":"NCT00363142","sponsor":"GlaxoSmithKline","briefTitle":"A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects","officialTitle":"See Detailed Description.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2006-08-15","resultsPosted":"2009-09-24","lastUpdate":"2010-11-05"},"enrollment":211,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infection","Infection, Human Immunodeficiency Virus"],"interventions":[{"type":"DRUG","name":"Half-boosted Fosamprenavir","otherNames":[]},{"type":"DRUG","name":"Full Boosted Fosamprenavir","otherNames":["Fosamprenavir","ritonavir"]}],"arms":[{"label":"FPV/r200","type":"ACTIVE_COMPARATOR"},{"label":"FPV/r100","type":"EXPERIMENTAL"}],"summary":"This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or once-daily.","primaryOutcome":{"measure":"Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"FPV/r100","deltaMin":92.1,"sd":null},{"arm":"FPV/r200","deltaMin":94.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":51,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["21126954"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7},"commonTop":["Diarrhea","Upper respiratory tract infection"]}}